rofecoxib

mitochondrially encoded cytochrome c oxidase II ; Homo sapiens







262 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
251 10215647 Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. 1999 May 2
252 10377455 Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. 1999 Jun 22 1
253 10383505 Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. 1999 Jun 1
254 10391112 Clinical experience with cyclooxygenase-2 inhibitors. 1999 May 1
255 10391671 Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. 1999 Jun 2
256 10406640 The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. 1999 Jul 5 3
257 10411562 Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. 1999 Aug 7
258 10414247 [Specific inhibitors of cyclo-oxygenase-2: a revolution?]. 1999 Jun 19 1
259 10500058 A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. 1999 Oct 1
260 10566565 The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. 1999 Oct 1
261 10580458 Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. 1999 Nov 24 1
262 10692773 Novel nonsteroidal anti-inflammatory drugs. 1999 Oct-Dec 1